The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse

Blood

Volumn 99, Issue 11, 2002, Pages 4100-4108

  Lock, Richard B ^a,b,c,d   Liem, Natalia ^a,b,c,d   Farnsworth, Monica L ^a,b,c,d   Milross, Christopher G ^a,b,c,d   Xue, Chengyuan ^a,b,c,d   Tajbakhsh, Mayamin ^a,b,c,d   Haber, Michalle ^a,b,c,d   Norris, Murray D ^a,b,c,d   Marshall, Glenn M ^a,b,c,d   Rice, Alison M ^a,b,c,d  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INFILTRATION; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SPLEEN; TUMOR XENOGRAFT;

EID: 0036624736     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.11.4100     Document Type: Article

References (23)

1. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997;90:4243-4251.
2. Pui C-H, Evans WE. Drug therapy: Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
3. Chessells JM. Relapsed lymphoblastic leukaemia in children: A continuing challenge. Br J Haematol. 1998;102:423-438.
4. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood. 1993;82:3163-3169.
5. Blau O, Avigad S, Stark B, et al. Exon 5 mutations in the p53 gene in relapsed childhood acute lymphoblastic leukemia. Leuk Res. 1997;21:721-729.
6. Drexler HG, Fombonne S, Matsuo Y, Hu Z-B, Hamaguchi H, Uphoff CC. p53 alterations in human leukemia-lymphoma cell lines: In vitro artifact or prerequisite for cell immortalization? Leukemia. 2000;14:198-206.
7. Uckun FM, Sather HN, Waurzyniak BJ, et al. Prognostic significance of B-lineage leukemic cell growth in SCID mice: A Children's Cancer Group study. Leuk Lymphoma. 1998;30:503-514.
8. Baersch G, Mollers T, Hotte A, et al. Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin Padiatr. 1997;209:178-185.
9. Steele JPC, Clutterbuck RD, Powles RL, et al. Growth of human T-cell lineage acute leukemia in severe combined immunodeficiency (SCID) mice and non-obese diabetic SCID mice. Blood. 1997;90:2015-2019.
10. Borgmann A, Baldy C, von Stackelberg A, et al. Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediat Hematol Oncol. 2000;17:635-650.
11. Rice AM, Wood JA, Milross CG, Collins CJ, McCarthy NF, Vowels MR. Conditions that enable human hematopoietic stem cell engraftment in all NOD-SCID mice. Transplantation. 2000;69:927-935.
12. Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, Falkenburg JHF. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol. 2001;29:322-329.
13. + cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model. Br J Haematol. 2001;114:433-443.
14. Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A. 1997;94:5320-5325.
15. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. 2nd Ed. Philadelphia, PA: Lippincott; 1993.
16. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia. Cancer, 1998;82:1387-1395.
17. Wang JCY, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 1998;91:2406-2414.
18. Rombouts WJC, Martens ACM, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia. 2000;14:889-897.
19. Dialynas DP, Lee M-J, Gold DP, et al. Preconditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice. Blood. 2001;97:3218-3225.
20. Hudson WA, Li Q, Le C, Kersey JH. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia. 1998;12:2029-2033.
21. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
22. Kamel-Reid S, Letarte M, Doedens M, et al. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood. 1991;78:2973-2981.
23. Kaspers GJL, Veerman AJP, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90:2723-2729.